- Home
- OBIO vs AGEN Comparison
OBIO vs AGEN Comparison
Compare OBIO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | AGEN |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | N/A | 316 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | OBIO | AGEN |
|---|---|---|
| Price | $4.47 | $3.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $14.00 | ★ $14.50 |
| AVG Volume (30 Days) | 299.6K | ★ 456.3K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,818,000.00 | ★ $106,829,000.00 |
| Revenue This Year | $36.43 | $67.15 |
| Revenue Next Year | $2.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $2.20 | $1.38 |
| 52 Week High | $6.30 | $7.34 |
Technical Indicators
Market Signals| Indicator | OBIO | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 37.31 |
| Support Level | $4.26 | $3.82 |
| Resistance Level | $4.64 | $4.12 |
| Average True Range (ATR) | 0.28 | 0.19 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 21.09 | 9.41 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).